{"id": "267247", "url": "https://fevir.net/resources/Citation/267247", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"], "versionId": "13", "lastUpdated": "2025-10-13T12:34:35.118Z"}, "title": "15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.", "author": [{"name": "Computable Publishing\u00ae: MEDLINE-to-FEvIR Converter"}], "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "contained": [{"id": "contributor0", "name": [{"given": ["Antona J"], "family": "Wagstaff"}], "resourceType": "Practitioner"}, {"id": "contributor1", "name": [{"given": ["Karen L"], "family": "Goa"}], "resourceType": "Practitioner"}, {"id": "meshHeading0", "content": [{"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "Yes"}]}]}], "classifier": [{"coding": [{"code": "Q000188", "system": "https://www.nlm.nih.gov/mesh", "display": "drug therapy"}]}]}], "classifier": [{"coding": [{"code": "D003924", "system": "https://www.nlm.nih.gov/mesh", "display": "Diabetes Mellitus, Type 2", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D006801", "system": "https://www.nlm.nih.gov/mesh", "display": "Humans", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "Yes"}]}]}], "classifier": [{"coding": [{"code": "Q000008", "system": "https://www.nlm.nih.gov/mesh", "display": "administration & dosage"}]}]}], "classifier": [{"coding": [{"code": "D007004", "system": "https://www.nlm.nih.gov/mesh", "display": "Hypoglycemic Agents", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D000077154", "system": "https://www.nlm.nih.gov/mesh", "display": "Rosiglitazone", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "Yes"}]}]}], "classifier": [{"coding": [{"code": "Q000008", "system": "https://www.nlm.nih.gov/mesh", "display": "administration & dosage"}]}]}], "classifier": [{"coding": [{"code": "D045162", "system": "https://www.nlm.nih.gov/mesh", "display": "Thiazolidinediones", "userSelected": false}]}], "freeToShare": true}], "resourceType": "ArtifactAssessment", "artifactReference": {"type": "Citation", "reference": "#"}}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "267247", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"value": "15832493", "system": "https://pubmed.ncbi.nlm.nih.gov"}], "statusDate": [{"period": {"end": "2005-04-19T09:00:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-pubmed", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Pubmed"}]}}, {"period": {"end": "2005-05-19T09:00:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-medline", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Medline"}]}}, {"period": {"end": "2005-04-19T09:00:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-entrez", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Entrez"}]}}], "useContext": [{"code": {"code": "fevir-platform-use", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"code": "medline-base", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Medline Base", "userSelected": false}]}}], "approvalDate": "2005-05-18", "currentState": [{"coding": [{"code": "medline-medline", "system": "http://hl7.org/fhir/citation-status-type", "display": "Medline Citation Status of Medline"}]}, {"coding": [{"code": "pubmed-publication-status-ppublish", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed PublicationStatus of ppublish"}]}], "resourceType": "Citation", "citedArtifact": {"title": [{"text": "Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.", "type": [{"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/title-type", "display": "Primary title"}]}], "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}}], "abstract": [{"text": "<AbstractText Label=\"UNLABELLED\">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of &lt; or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (&lt; or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.\n**CONCLUSIONS:** Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.", "type": {"coding": [{"code": "primary-human-use", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type", "display": "Primary human use"}]}}], "identifier": [{"value": "15832493", "system": "https://pubmed.ncbi.nlm.nih.gov"}, {"value": "10.2165/00024677-200201060-00006", "system": "https://doi.org"}], "webLocation": [{"url": "https://pubmed.ncbi.nlm.nih.gov/15832493/", "classifier": [{"coding": [{"code": "abstract", "system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "display": "Abstract"}]}]}], "classification": [{"type": {"coding": [{"code": "publishing-model", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Publishing Model", "userSelected": false}]}, "classifier": [{"coding": [{"code": "Print", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Print", "userSelected": false}]}]}, {"type": {"coding": [{"code": "chemical", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Chemical", "userSelected": false}]}, "classifier": [{"coding": [{"code": "D007004", "system": "https://www.nlm.nih.gov/mesh", "display": "Hypoglycemic Agents", "userSelected": false}]}, {"coding": [{"code": "D045162", "system": "https://www.nlm.nih.gov/mesh", "display": "Thiazolidinediones", "userSelected": false}]}, {"coding": [{"code": "05V02F2KDG", "system": "https://www.cas.org/support/documentation/chemical-substances", "userSelected": false}, {"code": "D000077154", "system": "https://www.nlm.nih.gov/mesh", "display": "Rosiglitazone", "userSelected": false}]}]}, {"type": {"coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "artifactAssessment": [{"type": "ArtifactAssessment", "reference": "#meshHeading0"}]}, {"type": {"coding": [{"code": "publication-type", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Publication type"}]}, "classifier": [{"coding": [{"code": "D016428", "system": "https://www.nlm.nih.gov/mesh", "display": "Journal Article", "userSelected": false}]}, {"coding": [{"code": "D016454", "system": "https://www.nlm.nih.gov/mesh", "display": "Review", "userSelected": false}]}]}, {"type": {"coding": [{"code": "knowledge-artifact-type", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Knowledge Artifact Type", "userSelected": false}]}, "classifier": [{"coding": [{"code": "D016428", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Journal Article", "userSelected": false}]}], "artifactAssessment": [{"display": "Classifier added by Computable Publishing LLC"}]}, {"type": {"coding": [{"code": "citation-subset", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Citation subset", "userSelected": false}]}, "classifier": [{"coding": [{"code": "IM", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset", "display": "IM", "userSelected": false}]}]}], "contributorship": {"entry": [{"affiliation": [{"display": "Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com"}], "contributor": {"type": "Practitioner", "display": "Wagstaff AJ", "reference": "#contributor0"}, "forenameInitials": "AJ"}, {"contributor": {"type": "Practitioner", "display": "Goa KL", "reference": "#contributor1"}, "forenameInitials": "KL"}], "complete": true}, "publicationForm": [{"issue": "6", "volume": "1", "pageString": "411-4", "articleDate": "2002", "citedMedium": {"coding": [{"code": "print", "system": "http://terminology.hl7.org/CodeSystem/cited-medium", "display": "Print"}]}, "publishedIn": {"type": {"coding": [{"code": "D020492", "system": "http://terminology.hl7.org/CodeSystem/published-in-type", "display": "Periodical"}]}, "title": "Treatments in endocrinology", "identifier": [{"type": {"text": "Print ISSN Type", "coding": [{"code": "Print", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn", "display": "Print"}]}, "value": "1175-6349", "system": "https://portal.issn.org"}, {"type": {"text": "ISOAbbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "Treat Endocrinol", "system": "https://www.issn.org/services/online-services/access-to-the-ltwa/"}, {"type": {"text": "ISSN Linking", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "1175-6349", "system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"}, {"type": {"text": "Medline Title Abbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "Treat Endocrinol", "system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"}, {"type": {"text": "NLM Unique ID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "101132977", "system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"}], "publisherLocation": "New Zealand"}}]}, "classification": [{"type": {"coding": [{"code": "citation-source", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "Citation Source"}]}, "classifier": [{"text": "MEDLINE"}]}, {"type": {"coding": [{"code": "medline-owner", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "MEDLINE Citation Owner"}]}, "classifier": [{"coding": [{"code": "NLM", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value", "display": "National Library of Medicine, Index Section", "userSelected": false}]}]}], "lastReviewDate": "2019-11-09", "description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."}